RedHill Biopharma (RDHL) Change in Cash (2016 - 2022)

RedHill Biopharma has reported Change in Cash over the past 11 years, most recently at $4.8 million for Q4 2022.

  • Quarterly Change in Cash fell 23.04% to $4.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$9.4 million through Dec 2022, down 3516.67% year-over-year, with the annual reading at -$644000.0 for FY2025, 32.99% up from the prior year.
  • Change in Cash was $4.8 million for Q4 2022 at RedHill Biopharma, up from -$11.8 million in the prior quarter.
  • Over five years, Change in Cash peaked at $52.5 million in Q1 2020 and troughed at -$59.4 million in Q2 2020.
  • The 5-year median for Change in Cash is $1.0 million (2019), against an average of $178300.0.
  • Year-over-year, Change in Cash skyrocketed 973.31% in 2020 and then plummeted 821.02% in 2021.
  • A 5-year view of Change in Cash shows it stood at $10.3 million in 2018, then surged by 67.7% to $17.3 million in 2019, then plummeted by 82.19% to $3.1 million in 2020, then skyrocketed by 101.13% to $6.2 million in 2021, then decreased by 23.04% to $4.8 million in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Change in Cash are $4.8 million (Q4 2022), -$11.8 million (Q3 2022), and -$1.8 million (Q2 2022).